Do GLP-1 Drugs Affect Muscle and Bone?

A new systematic review gives a measured answer to a common concern about GLP-1 medicines and muscle. Across 60 articles covering more than 1.25 million people, treatment was associated with a reduction in lean or fat-free mass, but the certainty of that evidence was low. The review did not find an adverse effect on bone mineral density, fractures or joint outcomes after its adjusted analyses^[1]. That means the lean-mass signal deserves attention, but it does not show that GLP-1 treatment causes clinically important muscle weakness.

The review included semaglutide, liraglutide, exenatide, dulaglutide and the dual GIP and GLP-1 agonist tirzepatide. It combined randomized trials with real-world evidence, so the headline is broader than a result for one drug or one patient group.

What the review actually measured

Researchers searched MEDLINE, Embase and the Cochrane trial register through March 2025. They included 46 randomized controlled trials, 13 real-world studies and one pharmacovigilance study. The outcomes covered bone mineral density and fractures, several measures of muscle mass, and joint measures such as WOMAC pain, stiffness and physical function. WOMAC is a questionnaire commonly used to assess osteoarthritis symptoms and function^[1].

The populations and methods varied sharply. Individual studies ranged from 15 participants to hundreds of thousands, while treatment lasted from less than three weeks to several years. Included populations covered obesity, diabetes and several more specific clinical settings, while the researchers grouped different medicines and comparators. That breadth helps detect patterns, but it also makes a single pooled estimate harder to apply to one person taking one drug^[1].

The lean-mass finding needs context

Twenty-eight studies reported lean body mass or fat-free mass. The pooled analysis found a reduction with GLP-1 receptor agonists, and the result remained in the authors' sensitivity analyses. Subgroup results suggested that liraglutide and semaglutide treatment drove much of the observed effect. The authors rated the certainty as low and reported high statistical heterogeneity, meaning the study results differed substantially from one another^[1].

Lean mass is not the same thing as working skeletal muscle. Measurements can include water, organs and other non-fat tissue, depending on the method. The review also concluded that the reductions appeared largely related to overall weight loss. It could not establish whether the measured change led to weaker grip, poorer walking performance or a meaningful loss of independence^[1]. Those functional outcomes are the questions patients and clinicians usually care about most.

The main STEP 1 trial helps explain the scale of the weight change behind this discussion. In adults with overweight or obesity without diabetes, weekly semaglutide plus lifestyle intervention produced a mean 14.9% reduction in body weight at 68 weeks, compared with 2.4% on placebo. Participants also reported greater improvement in physical functioning than the placebo group^[2]. STEP 1 did not settle whether a change in lean mass translates into worse muscle function.

Bone and joint results were neutral

The adjusted models found no effect on bone mineral density at the lumbar spine, femoral neck, total hip or total body. The analysis also found no effect on hip fracture, major osteoporotic fracture or fractures overall. An apparent reduction in vertebral fractures disappeared when the researchers used the most adjusted effect estimates^[1]. A neutral result is not proof of protection, but this review did not find evidence that the class worsened those bone outcomes.

Joint findings were similarly cautious. Pooled models showed no significant change in WOMAC pain, physical function or stiffness. The evidence base was much smaller for joint outcomes than for fractures or lean mass, so the result should not be read as a final answer about every form of arthritis or every GLP-1 medicine^[1].

What this means for patients

The useful takeaway is not that muscle loss is inevitable. It is that body composition and physical function are separate outcomes, and current studies measure the first more often than the second. Someone using tirzepatide or semaglutide under clinical care can ask how strength, mobility, nutrition and total weight loss are being assessed together. The review does not support changing or stopping a prescribed medicine without a clinician^[1].

The findings also do not justify assuming that a specific exercise or supplement plan will prevent lean-mass change. This meta-analysis did not test a single prevention protocol. Questions about resistance training, protein intake or treatment choice need to account for age, medical history and the reason the medicine was prescribed. Our semaglutide evidence page and tirzepatide evidence page cover the wider safety context.

What we still do not know

The review leaves three practical gaps. It cannot tell us whether lean-mass changes differ meaningfully among individual drugs. Nor can it show whether those changes cause loss of strength or physical performance. Separating treatment effects cleanly from the effects of losing substantial body weight also remains difficult. The authors call for studies that measure muscle function, strength and performance while adjusting for confounding factors^[1].

Longer follow-up will matter, especially for older adults and people already at risk of frailty. Until those data arrive, the most accurate reading is narrow: the pooled literature identifies a low-certainty lean-mass signal, while adjusted bone and joint outcomes were neutral. Readers can follow our GLP-1 coverage as functional-outcome studies develop.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.